Section 01
What it's used for
Type 2 Diabetes (Approved Drug)
FDA-approved for blood sugar control in type 2 diabetes and lower cardiovascular risk. In trials, HbA1c fell about 0.7-0.8% alone (AWARD-3) up to 1.4% with metformin (AWARD-6); weight loss was seen but no exact kilogram figure is confirmed.
▸Clinical wording
Dulaglutide is FDA-approved for glycemic control in type 2 diabetes and for cardiovascular risk reduction. Reported HbA1c reductions vary by trial and dose: pivotal trials show reductions from about -0.7% to -0.8% as monotherapy (AWARD-3) up to about -1.4% when added to metformin (AWARD-6), a wider range than a flat 1.1-1.5%. These pivotal-trial publications describe weight loss without giving a specific kilogram figure, so a precise 2-4 kg range is not confirmed from primary sources.
Cardiovascular Risk (REWIND Trial)
In the REWIND trial of 9,901 people with type 2 diabetes, dulaglutide cut major cardiovascular events by 12% (HR 0.88, p=0.026), including many without prior heart disease. Broader "first" claims aren't confirmed by the trial paper.
▸Clinical wording
The REWIND trial found that dulaglutide reduced major adverse cardiovascular events by 12% (HR 0.88, 95% CI 0.79-0.99, p=0.026) in 9,901 patients with type 2 diabetes who had established cardiovascular disease or cardiovascular risk factors, including many without prior cardiovascular disease. The trial's own publication does not describe dulaglutide as the first GLP-1 receptor agonist to demonstrate cardiovascular benefit across the full risk spectrum; that characterization was not found in the primary source and should not be presented as an established finding of the trial itself.
Section 02
Mechanism of Action
A gut hormone fused to an antibody
- Dulaglutide joins two copies of a modified gut hormone sequence to an antibody tail.
- The antibody tail was altered to lower immune reactions and prevent half-molecule formation.
- In laboratory tests the construct was about four times more potent than the protected hormone alone.
- In receptor assays it kept full activity and released insulin from isolated islets like the natural hormone.
▸Clinical wording
DPP-4-resistant GLP-1 analogue fused to an IgG4 Fc
Dulaglutide is built from two identical disulfide-linked chains, each carrying an N-terminal GLP-1(7-37) analogue sequence joined by a (Gly4Ser)3Ala peptide linker to a modified human IgG4 heavy chain (Liu, 2024). The Fc was altered to reduce interactions with high-affinity Fc receptors, eliminate half-antibody formation and reduce cell-mediated cytotoxicity, lowering immunogenic potential; in vitro the construct was about fourfold more potent than the unmodified DPP-4-protected GLP-1 peptide (Amblee, 2016). In receptor assays it retained full GLP-1 receptor activity and gave insulinotropic responses in isolated islets similar to the native peptide (Glaesner et al., 2010).
Why the dose is weekly, not daily
- The large size slows clearance by the kidney rather than changing how the receptor is activated.
- In rats and monkeys the half-life was one and a half to two days, with activity past six days.
- In patients with type 2 diabetes peak levels came near 48 hours and half-life was about five days.
- Steady levels were reached between the second and the fourth weekly dose.
▸Clinical wording
Size-driven clearance and once-weekly exposure
Fusion to a large carrier changes elimination rather than receptor pharmacology: the large molecular entities of albiglutide and dulaglutide delay their renal clearance (Liu, 2024). In rats and cynomolgus monkeys the half-life was 1.5-2 days and serum immunoreactivity representing active compound persisted beyond six days after a single dose (Glaesner et al., 2010). Population pharmacokinetics in patients with type 2 diabetes fitted a two-compartment model with first-order absorption and elimination: maximum concentration near 48 hours, terminal half-life about five days, clearance 0.126 L/h, steady state reached between the second and fourth weekly dose (Geiser et al., 2016).
Insulin release only when sugar is high
- The receptor raises an internal messenger in the insulin cell, and that signal splits into two branches.
- Both branches act only after sugar breakdown lowers a cell energy signal (ADP), the basis of glucose dependence.
- In a meal test of 409 patients, insulin cell function rose on both doses and was unchanged on metformin.
- Insulin sensitivity instead improved more with metformin than with dulaglutide.
▸Clinical wording
Glucose-dependent beta-cell signalling and secretion
At the beta cell the GLP-1 receptor couples through G-alpha-s to adenylyl cyclase, and cAMP splits into two branches: PKA phosphorylates the KATP subunit SUR1 to displace ADP, while Epac2 lowers the ATP needed to inhibit the channel. Both work only once glucose metabolism has lowered ADP, the structural basis of glucose dependence (Meloni et al., 2013). In an AWARD-3 meal-test substudy of 409 patients, beta-cell function (AUCinsulin/AUCglucose) rose on both dulaglutide doses and was unchanged on metformin, insulin secretion rate at 9 mmol/L glucose rose on both doses, and glucose sensitivity improved at 1.5 mg; insulin sensitivity instead rose more with metformin (Mari et al., 2016).
Slower stomach, less food, lower weight
- This drug class slows gut movement through vagus nerve signals and direct central stimulation.
- Long-acting agents show fading of that slowing over time.
- Modelling of a painkiller's absorption found no clinically relevant effect on small-molecule handling.
- In one trial weight fell 3.0 kg on the lower dose and 4.6 kg on the higher at 36 weeks.
▸Clinical wording
Gastric emptying, appetite and body weight
GLP-1 receptor agonists inhibit gastrointestinal motor function through vagal afferents and direct central stimulation, and long-acting agents show tachyphylaxis (Jalleh et al., 2024). In rats, GLP-1 receptors sit on nodose ganglion neurons and vagal terminals, and the area postrema, outside the blood-brain barrier, gives peripheral GLP-1 access to autonomic sites (Liu, 2024). For dulaglutide the delay is exposure-dependent, though modelling of acetaminophen absorption found no clinically relevant effect on small-molecule pharmacokinetics at 1.5 or 4.5 mg (Posada et al., 2025). Body weight tracked dose in AWARD-11: -3.0 kg on 1.5 mg versus -4.6 kg on 4.5 mg at 36 weeks (Frias et al., 2021).
What long trials measured over years
- In a trial of 9901 people followed 5.4 years, major heart events occurred in 12.0 versus 13.4 percent.
- Death from any cause did not differ between the dulaglutide and placebo groups.
- An exploratory kidney analysis found 17.1 versus 19.6 percent, driven mainly by new protein in urine.
- A cognitive analysis found no unadjusted difference; a difference appeared only after adjusting for baseline scores.
▸Clinical wording
Vascular, renal and cognitive signals over years
In REWIND, 9901 participants were followed a median of 5.4 years. The composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke occurred in 12.0% on dulaglutide versus 13.4% on placebo (HR 0.88, 95% CI 0.79-0.99), while all-cause mortality did not differ (Gerstein et al., 2019a). An exploratory renal analysis of the same cohort found the composite renal outcome in 17.1% versus 19.6% (HR 0.85), driven mainly by new macroalbuminuria (Gerstein et al., 2019b). A cognitive analysis of 8828 participants found no unadjusted difference; adjusted for baseline scores the hazard ratio for substantive cognitive impairment was 0.86 (Cukierman-Yaffe et al., 2020).
Section 03
Biological Pathways
- IgG4 Fc-fused GLP-1 analogue designTwo DPP-4-resistant GLP-1 analogue chains fuse via a linker to a modified IgG4 Fc cutting Fc-receptor binding and cytotoxicity; the construct kept full receptor activity, matching native peptide potency in islets.
- Size-driven clearance for weekly dosingThe large Fc-fused molecule delays renal clearance rather than altering receptor pharmacology; half-life ran 1.5-2 days in animals, and in patients it reached steady state by the second to fourth weekly dose.
- Glucose-dependent beta-cell cAMP/PKA/Epac2GLP-1 receptor coupling to adenylyl cyclase raises cAMP, splitting into a PKA branch that displaces ADP from SUR1 and an Epac2 branch lowering the ATP needed to shut the KATP channel, once glucose has lowered ADP.
- Vagal and central appetite signallingGLP-1 receptors on nodose ganglion neurons and vagal terminals, plus direct access via the area postrema, slow gastric emptying and appetite; weight loss was -3.0 kg versus -4.6 kg on the higher dose at 36 weeks.
Section 04
Dosage Information
GLP-1 analog fused to modified IgG4 Fc domain| Route / system | Context | Range studied | Limitation |
|---|---|---|---|
| Subcutaneous — approved dose, adults | FDA label for type 2 diabetes (Trulicity) | 0.75 mg a week to start, 1.5 mg after 4 weeks, then 1.5 mg steps no sooner than every 4 weeks, to a 4.5 mg maximum — 50–64 µg/kg a week | Four fixed pen strengths, nothing in between, no adjustment for weight or kidneys. Never approved for obesity anywhere; the 4.5 mg limit came from blood sugar. |
| Subcutaneous — dose-comparison trial | Phase 3, type 2 diabetes, all on metformin | 1.5 vs 3 vs 4.5 mg once a week in 1,842 adults over 36 weeks; weight fell 3.1 kg on 1.5 mg and 4.7 kg on 4.5 mg | Tripling the dose bought 1.6 kg over 36 weeks. Everyone had diabetes and was already on metformin, and weight was a side measurement, not the goal. |
| Subcutaneous — long-term heart trial | Heart-outcome trial in type 2 diabetes | 1.5 mg once a week in 9,901 adults with type 2 diabetes, median 5.4 years; major heart events 12.0% vs 13.4% on placebo | The only dose with outcomes measured in years. The 3 mg and 4.5 mg strengths have no heart trial behind them, and none of this covers people without diabetes. |
| Subcutaneous — approved dose, children | FDA label, type 2 diabetes, ages 10 and up | 0.75 mg once a week, raised to at most 1.5 mg after 4 weeks or more — a third of the adult ceiling, about 17–21 µg/kg a week | The 3 mg and 4.5 mg strengths were never studied under 18. The dose stays a flat milligram figure: a 35 kg child gets the same as a 90 kg teenager. |
Results
Syringe Fill Level (100u syringe)
Set positive values for: Recommended dose per kg.
Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.
Section 05
Protocols
No protocols featuring this peptide yet. Browse All Protocols
Section 06
Stability & Storage
Storing the product
Each single-dose Trulicity pen is kept refrigerated at 2-8 °C and is not frozen. Every pen delivers one fixed dose — 0.75 mg, 1.5 mg, 3.0 mg, or 4.5 mg — for a single use.
After opening
If refrigeration is unavailable, an unused pen may instead be kept at room temperature (up to 30 °C) for up to 14 days before use. Beyond that window no further room-temperature storage is described.
Section 07
Side Effects & Precautions
Dulaglutide's most common side effects are digestive, alongside a few less common risks.
Digestive effects
Nausea affects 12-21% of patients, diarrhea 8-12%, and vomiting 6-12%. Abdominal pain and decreased appetite can also occur. This digestive profile is generally milder than short-acting GLP-1 receptor agonists.
Injection site reactions
These occur in 1-2% of patients.
Rare but serious risks
- Pancreatitis is a rare risk.
- There is a thyroid C-cell warning.
Antibody response
Antibodies against the drug develop in about 1% of patients.
Section 08
Regulatory Status
FDA / United States
Approved in 2014 as Trulicity
The label was expanded in 2020 to include reduction of major adverse cardiovascular events in adults with type 2 diabetes, based on the REWIND outcomes trial.
EMA / Europe
Approved for the same indications
Trulicity holds EU marketing authorisation for type 2 diabetes and, following REWIND, for cardiovascular risk reduction, on the same schedule as in the US.
WADA
Not prohibited
GLP-1 receptor agonists, dulaglutide included, do not appear in the S2 or S4 sections of the 2026 Prohibited List; USADA confirms the class is not banned in sport.
Biosimilar pipeline
Still exclusively brand-name
Trulicity's core patents begin expiring from 2025, but no biosimilar dulaglutide has reached the market yet — the first is not expected before late 2027.
Regulatory status differs by country and changes over time. The 2020 cardiovascular indication and the older 2014 diabetes indication carry different evidence bases — check the current label of your own regulator.
Section 09
Research Studies
- [1]Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion proteinGlaesner W, Vick AM, Millican R, Ellis B, Tschang SH, Tian Y, Bokvist K, Brenner M, Koester A, Porksen N, Etgen G, Bumol T. · Diabetes/Metabolism Research and Reviews · 2010
- [2]Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical TrialsGeiser JS, Heathman MA, Cui X, Martin J, Loghin C, Chien JY, de la Pena A. · Clinical Pharmacokinetics · 2016
- [3]Mode of administration of dulaglutide: implications for treatment adherenceAmblee A. · Patient Preference and Adherence · 2016
- [4]Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonistsLiu QK. · Frontiers in Endocrinology · 2024
- [5]GLP-1 receptor activated insulin secretion from pancreatic beta-cells: mechanism and glucose dependenceMeloni AR, DeYoung MB, Lowe C, Parkes DG. · Diabetes, Obesity and Metabolism · 2013
- [6]Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic beta-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetesMari A, Del Prato S, Ludvik B, Milicevic Z, de la Pena A, Shurzinske L, Karanikas CA, Pechtner V. · Diabetes, Obesity and Metabolism · 2016
- [7]Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and TirzepatideJalleh RJ, Plummer MP, Marathe CS, et al. · Journal of Clinical Endocrinology and Metabolism · 2024
- [8]A Combined Modeling Approach to Predict the Effect of Gastric Emptying Delay on the Pharmacokinetics of Small MoleculesPosada MM, Schneck KB, Morse BL, Rougee LRA, Tham LS, Rehmel JF, Thompson B, Stamatis SD, Hall SD, Dickinson GL. · CPT: Pharmacometrics and Systems Pharmacology · 2025
- [9]Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)Frias JP, Bonora E, Nevarez Ruiz L, Li YG, Yu Z, Milicevic Z, Malik R, Bethel MA, Cox DA. · Diabetes Care · 2021
- [10]Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialGerstein HC, Colhoun HM, Dagenais GR, et al. · Lancet · 2019
- [11]Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trialGerstein HC, Colhoun HM, Dagenais GR, et al. · Lancet · 2019
- [12]Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trialCukierman-Yaffe T, Gerstein HC, Colhoun HM, et al. · Lancet Neurology · 2020
Section 10
Frequently Asked Questions
Dulaglutide is a fusion protein: a modified GLP-1 peptide linked to an altered human IgG4 antibody fragment (Fc domain), which is what gives it a roughly 5-day half-life and allows once-weekly dosing instead of the daily injections earlier GLP-1 drugs required. This antibody-fragment fusion is a structurally different approach from other long-acting GLP-1 drugs, though the material reviewed here doesn't include a head-to-head comparison against them.
Weight loss data come from a diabetes trial, not a dedicated obesity study: in patients also on metformin, 1.5 mg a week produced 3.1 kg of weight loss and 4.5 mg produced 4.7 kg over 36 weeks — tripling the dose bought only 1.6 kg more. Weight loss was a secondary measurement, not the trial's purpose, and dulaglutide has never been approved for weight loss on its own; every study behind it enrolled people with type 2 diabetes.
In the REWIND trial — 9,901 people with type 2 diabetes, most without established heart disease but with cardiovascular risk factors — dulaglutide 1.5 mg weekly reduced major cardiovascular events over a median 5.4 years, 12.0% versus 13.4% on placebo (HR 0.88, p=0.026). The trial didn't test the higher 3 mg or 4.5 mg doses, and its own publication doesn't claim dulaglutide was the first GLP-1 drug to show benefit across the full cardiovascular risk spectrum — that framing isn't supported by the primary report.
The FDA label starts at 0.75 mg once a week, raises to 1.5 mg after 4 weeks, and can step up further to a 3 mg or 4.5 mg maximum, with increases spaced at least 4 weeks apart. There are four fixed pen strengths with nothing adjustable in between, and no dose is modified for body weight or kidney function.
The most common effects are gastrointestinal: nausea in 12-21%, diarrhoea in 8-12%, vomiting in 6-12%, plus abdominal pain and decreased appetite — generally milder than shorter-acting GLP-1 drugs. Less common effects include injection-site reactions (1-2%), rare pancreatitis, and a warning about thyroid C-cell tumours; about 1% of patients develop anti-drug antibodies.
No. GLP-1 receptor agonists are not on the WADA Prohibited List, and no therapeutic use exemption is required for them. Drugs in this class have been on WADA's monitoring programme since 2024, where laboratories track patterns of use without sanctions, and whether to prohibit the class is under discussion ahead of the 2028 Games.
Each single-use Trulicity pen is stored refrigerated at 2-8°C and must not be frozen; every pen delivers one fixed dose. If refrigeration isn't available, an unused pen can be kept at room temperature, up to 30°C, for up to 14 days before use — beyond that window no further room-temperature storage is documented.